TREM-1 platform for oncology, immunology, and autoimmune
Ligand-independent mechanisms of TREM-1 blockade and excellent safety and tolerability of SignaBlok's first-in-class TREM-1 therapy minimize risk of drug failure in the clinic.
In oncology, TREM-1 therapy suppresses inflammation and prevents tumor growth and metastasis as well as cancer recurrence. In experimental cancer, SignaBlok's TREM-1 inhibitors:
- standalone - inhibit tumor growth and extend survival
- in combination with chemo- and immunotherapy - sensitize hard-to-treat tumors to cancer treatment, synergistically inhibit tumor growth, prevent cancer recurrence, 3X increase complete response rate and survival.
In rheumatoid arthritis, multiple sclerosis and scleroderma, SignaBlok's TREM-1 therapy suppresses detrimental innate immune inflammation and ameliorates the disease. In animal models, SignaBlok's TREM-1 inhibitors:
- diminish release of proinflammatory cytokines
- suppress joint inflammation and damage (rheumatoid arthritis)
- prevent and reverse skin fibrosis (scleroderma)
In retinopathy, TREM-1 therapy prevents and treats retinal neovascularization. Granted Orphan Drug Designation by FDA in 2026 for Retinopathy of Prematurity (ROP) In animal models, SignaBlok's TREM-1 inhibitors:
- diminish release of proinflammatory cytokines
- suppress pathological angiogenesis
- prevent and treat retinal neovascularization
In sepsis and infectious diseases, TREM-1 therapy suppresses cytokine storm and ameliorates the disease, while preserving immunity. In animal models, SignaBlok's TREM-1 inhibitors:
- suppress systemic inflammation and protect from death even at later administration times (sepsis)
- treat virus- and bacteria-induced pulmonary neutrophilia and inflammation (pertusis, acute lung injury)
In lung diseases, TREM-1 therapy ameliorates the disease. In animal models, SignaBlok's TREM-1 inhibitors:
- suppress lung inflammation and inhibit infiltration of neutrophils into the lungs
- prevent and reverse pulmonary fibrosis
About SignaBlok, Inc.
SignaBlok, Inc. is a biopharmaceutical company founded in 2009 that focuses on developing novel mechanism-based targeted therapeutics and nanosystems for delivery and diagnostic imaging [1]. The company utilizes its proprietary Signaling Chain HOmoOLigomerization (SCHOOL) platform, which enables ligand-independent drug development for immune receptor signaling modulation [2][4]. This approach aims to address significant limitations found in traditional ligand-dependent models, offering potential applications across a wide range of inflammation-associated conditions, including cancer, autoimmune diseases, retinopathy, and sepsis [3][4].
By targeting specific pathways such as TREM-1 and TREM-2, SignaBlok seeks to provide innovative interventions for diseases characterized by unmet clinical needs [3][4]. The company maintains an extensive intellectual property portfolio that supports its drug discovery and diagnostic development efforts [7]. Through strategic partnerships and collaborations, SignaBlok works to translate its scientific research into practical medical solutions for patients [8]. The organization is led by Dr. Alexander B. Sigalov, whose experience in fields including immunology and biophysics guides the company’s ongoing pipeline development [1].
delivered to your inbox.